Sean Cross, CFO, Pacira : Where it is dosed in very small amounts. We just call it micro dosing into the into the joint, into the knee. So there's no to very limited systemic exposure. So you don't have the safety concerns associated with the systemic flooding in in the rare diseases. And then that's also important with regard to a cost perspective.